

# Narendra Chirmule

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8223386/publications.pdf>

Version: 2024-02-01

65  
papers

6,251  
citations

126858

33  
h-index

118793

62  
g-index

68  
all docs

68  
docs citations

68  
times ranked

5483  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. <i>Molecular Genetics and Metabolism</i> , 2003, 80, 148-158.	0.5	1,309
2	Gene Therapy Vectors Based on Adeno-Associated Virus Type 1. <i>Journal of Virology</i> , 1999, 73, 3994-4003.	1.5	484
3	Acute Cytokine Response to Systemic Adenoviral Vectors in Mice Is Mediated by Dendritic Cells and Macrophages. <i>Molecular Therapy</i> , 2001, 3, 697-707.	3.7	367
4	A Pilot Study of In Vivo Liver-Directed Gene Transfer with an Adenoviral Vector in Partial Ornithine Transcarbamylase Deficiency. <i>Human Gene Therapy</i> , 2002, 13, 163-175.	1.4	337
5	Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy. <i>AAPS Journal</i> , 2012, 14, 296-302.	2.2	262
6	Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay. <i>Vaccine Journal</i> , 2003, 10, 108-115.	3.2	245
7	Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway. <i>Science</i> , 1997, 275, 1481-1485.	6.0	223
8	Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18. <i>Vaccine Journal</i> , 2005, 12, 959-969.	3.2	222
9	Stealth Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung. <i>Journal of Virology</i> , 2001, 75, 4792-4801.	1.5	221
10	Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer. <i>Journal of Virology</i> , 2001, 75, 6199-6203.	1.5	203
11	Purification of Recombinant Adeno-Associated Virus Vectors by Column Chromatography and Its Performance in Vivo. <i>Human Gene Therapy</i> , 2000, 11, 2079-2091.	1.4	176
12	Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle. <i>Journal of Virology</i> , 2000, 74, 2420-2425.	1.5	174
13	PEGylation of E1-Deleted Adenovirus Vectors Allows Significant Gene Expression on Readministration to Liver. <i>Human Gene Therapy</i> , 2002, 13, 1887-1900.	1.4	166
14	Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. <i>Journal of Immunology Research</i> , 2016, 2016, 1-18.	0.9	154
15	A Phase I Study of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to a Lung Segment of Individuals with Cystic Fibrosis. <i>Human Gene Therapy</i> , 1999, 10, 2973-2985.	1.4	138
16	Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies. <i>Human Gene Therapy</i> , 2001, 12, 205-215.	1.4	138
17	CD40 Ligand-Dependent Activation of Cytotoxic T Lymphocytes by Adeno-Associated Virus Vectors In Vivo: Role of Immature Dendritic Cells. <i>Journal of Virology</i> , 2000, 74, 8003-8010.	1.5	110
18	Route of Administration Determines Induction of T-Cell-Independent Humoral Responses to Adeno-Associated Virus Vectors. <i>Molecular Therapy</i> , 2000, 1, 323-329.	3.7	108

#	ARTICLE	IF	CITATIONS
19	Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. <i>Clinical Immunology</i> , 2010, 137, 5-14.	1.4	73
20	Enhanced Rates and Magnitude of Immune Responses Detected against an HIV Vaccine: Effect of Using an Optimized Process for Isolating PBMC. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 86-92.	0.5	71
21	A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres. <i>Journal of Immunological Methods</i> , 2006, 309, 75-85.	0.6	70
22	Role of E4 in Eliciting CD4 T-Cell and B-Cell Responses to Adenovirus Vectors Delivered to Murine and Nonhuman Primate Lungs. <i>Journal of Virology</i> , 1998, 72, 6138-6145.	1.5	70
23	Blockade of Interferon- $\beta$ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2713-2722.	2.9	60
24	Readministration of Adenovirus Vector in Nonhuman Primate Lungs by Blockade of CD40-CD40 Ligand Interactions. <i>Journal of Virology</i> , 2000, 74, 3345-3352.	1.5	59
25	Identification and inhibition of drug target interference in immunogenicity assays. <i>Journal of Immunological Methods</i> , 2010, 355, 21-28.	0.6	57
26	Partial Correction of Murine Hemophilia A with Neo-Antigenic Murine Factor VIII. <i>Human Gene Therapy</i> , 2000, 11, 881-894.	1.4	56
27	HIV-1 Envelope Glycoproteins Induce Activation of Activated Protein-1 in CD4+ T Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 19364-19369.	1.6	51
28	Additional Transduction Events after Subretinal Readministration of Recombinant Adeno-Associated Virus. <i>Human Gene Therapy</i> , 2000, 11, 449-457.	1.4	51
29	The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. <i>Journal of Medical Virology</i> , 2006, 78, 1679-1687.	2.5	48
30	Characterization of the Immune Response After Local Delivery of Recombinant Adenovirus in Murine Pancreas and Successful Strategies for Readministration. <i>Human Gene Therapy</i> , 1997, 8, 2207-2216.	1.4	42
31	Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics. <i>AAPS Journal</i> , 2013, 15, 30-40.	2.2	37
32	Fas-Fas Ligand Interactions Play a Major Role in Effector Functions of Cytotoxic T Lymphocytes after Adenovirus Vector-Mediated Gene Transfer. <i>Human Gene Therapy</i> , 1999, 10, 259-269.	1.4	34
33	Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. <i>Bioanalysis</i> , 2013, 5, 1041-1055.	0.6	33
34	Biology of E1-Deleted Adenovirus Vectors in Nonhuman Primate Muscle. <i>Journal of Virology</i> , 2001, 75, 5222-5229.	1.5	32
35	Enzyme-Linked Immunosorbent Assay for Measuring Antibodies to Pneumococcal Polysaccharides for the PNEUMOVAX 23 Vaccine: Assay Operating Characteristics and Correlation to the WHO International Assay. <i>Vaccine Journal</i> , 2006, 13, 905-912.	3.2	29
36	Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. <i>Annals of Hematology</i> , 2010, 89, 75-85.	0.8	28

#	ARTICLE	IF	CITATIONS
37	Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. <i>Bioanalysis</i> , 2014, 6, 1509-1523.	0.6	27
38	Misinterpretation of results of cytokine bioassays. <i>Journal of Immunological Methods</i> , 1991, 137, 141-144.	0.6	25
39	Signals Transduced through the CD4 Molecule Interfere with TCR/CD3-Mediated Ras Activation Leading to T Cell Anergy/Apoptosis. <i>Clinical Immunology and Immunopathology</i> , 1997, 85, 195-201.	2.1	24
40	Improved Specificity of In Vitro Anti-HIV Antibody Production: Implications for Diagnosis and Timing of Transmission in Infants Born to HIV-Seropositive Mothers. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 691-699.	0.5	22
41	Innate Immune Responses to Adenoviral Vector-Mediated Acute Pancreatitis. <i>Pancreas</i> , 2005, 30, 122-129.	0.5	22
42	Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 688-693.	0.4	22
43	Th2-Dependent B Cell Responses in the Absence of CD40-CD40 Ligand Interactions. <i>Journal of Immunology</i> , 2000, 164, 248-255.	0.4	18
44	Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. <i>Bioanalysis</i> , 2010, 2, 721-731.	0.6	16
45	Assessing specificity for immunogenicity assays. <i>Bioanalysis</i> , 2009, 1, 611-617.	0.6	15
46	Measurement of Anti-Erythropoiesis-Stimulating Agent IgG4 Antibody as an Indicator of Antibody-Mediated Pure Red Cell Aplasia. <i>Vaccine Journal</i> , 2013, 20, 46-51.	3.2	15
47	Immunological Characteristics of HIV-Infected Children: Relationship to Age, CD4 Counts, Disease Progression, and Survival. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1209-1219.	0.5	12
48	Development of an Adenovirus-Shedding Assay for the Detection of Adenoviral Vector-Based Vaccine and Gene Therapy Products in Clinical Specimens. <i>Human Gene Therapy</i> , 2003, 14, 25-36.	1.4	12
49	Envelope Glycoproteins of HIV-1 Interfere with T-Cell-Dependent B Cell Differentiation: Role of CD4-MHC Class II Interaction in the Effector Phase of T Cell Help. <i>Cellular Immunology</i> , 1994, 155, 169-182.	1.4	11
50	The HIV Glycoprotein gp160 Has Superantigen-like Properties. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 255-265.	2.1	11
51	Adenoviral Vector-Mediated Gene Therapy in the Mouse Lung: No Role of Fas-Fas Ligand Interactions for Elimination of Transgene Expression in Bronchioepithelial Cells. <i>Human Gene Therapy</i> , 1999, 10, 2839-2846.	1.4	9
52	CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes. <i>Cytotherapy</i> , 2022, 24, 101-109.	0.3	9
53	Comparing Exponentially Weighted Moving Average and Run Rules in Process Control of Semiquantitative Immunogenicity Immunoassays. <i>AAPS Journal</i> , 2010, 12, 79-86.	2.2	8
54	Development and validation of a cell based assay for the detection of neutralizing antibodies against recombinant insulins. <i>Journal of Immunological Methods</i> , 2018, 452, 53-62.	0.6	7

#	ARTICLE	IF	CITATIONS
55	A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development. AAPS Journal, 2009, 11, 526-34.	2.2	6
56	Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. AAPS Journal, 2017, 19, 447-455.	2.2	5
57	Development and validation of an electrochemiluminescent ELISA for quantitation of oral insulin tregopil in diabetes mellitus serum. Bioanalysis, 2017, 9, 975-986.	0.6	4
58	Mentoring during the COVID-19 pandemic: a perspective from graduate students in biomedical science studies in India. Proceedings of the Indian National Science Academy, 2021, 87, 320-323.	0.5	3
59	Biopharmaceutical Development in India: Recommendations on Collaboration and Innovation to Enable Affordable Healthcare. , 2021, , 255-281.		3
60	Recommendations for Enhancing Quality and Capability of Indian Biopharmaceutical Industry: Summary of a Workshop. Journal of Pharmaceutical Sciences, 2020, 109, 2958-2961.	1.6	2
61	Failure Mode and Effects Analysis (FMEA) for Immunogenicity of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2020, 109, 3214-3222.	1.6	2
62	Elimination of rheumatoid factor interference in immunoassays using the electrochemiluminescence (ECL) based Meso Scale Discovery (MSD) platform. FASEB Journal, 2008, 22, 566-566.	0.2	2
63	Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation. Journal of Immunological Methods, 2015, 425, 88-96.	0.6	1
64	Correlation of in silico prediction of immunogenicity of therapeutic proteins with immune responses in clinical studies.. FASEB Journal, 2008, 22, 563-563.	0.2	0
65	Advanced strategies in glycosylation prediction and control during biopharmaceutical development: Avenues toward industry 4.0. Biotechnology Progress, 2022, 38, .	1.3	0